Clinical Research Papers:
Lymphovascular invasion is a high risk factor for stage I/II colorectal cancer: a systematic review and meta-analysis
PDF | HTML | How to cite
Metrics: PDF 1731 views | HTML 2820 views | ?
Hang Yuan1,2,*, Quanjin Dong1,*, Bo’an Zheng1, Xinye Hu1, Jian-Bo Xu3 and Shiliang Tu1
1 The Surgical Department of Coloproctology, Zhejiang Provincial People’s Hospital, Hangzhou, China
2 Nanjing Medical University, Nanjing, China
3 Department of Hepatobiliary Surgery, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an City, China
* These authors have contributed equally to this work
Jian-Bo Xu, email:
Shiliang Tu, email:
Keywords: lymphovascular invasion, survival, stage I/II, colorectal cancer, meta-analysis
Received: January 04, 2017 Accepted: February 08, 2017 Published: February 16, 2017
The prognostic value of lymphovascular invasion (LVI) in stage I/II colorectal cancer (CRC) does not reach a consensus. To systematically assess prognostic significance of LVI, databases of PubMed, Web of Science, and Embase were searched from inception up to 10 Dec 2016. The pooled hazard ratio (HR) and 95% confidence intervals (CI) were used to determine the prognostic effects. Nineteen relevant studies including 9881 total patients were enrolled. Our results showed that LVI is significantly associated with poor prognosis in overall survival (OS) (HR=2.15, 95 % CI=1.72–2.68, P < 0.01) and disease-free survival (DFS) (HR=1.73, 95% CI=1.50–1.99, P < 0.01), which is similar in stage II patients. Further subgroup analysis revealed that the significance of the association between LVI and worse prognosis in CRC patients is not affected by below factors, including geographic setting, LVI positive rate, treatment, tumor site, and quality of the study. The current meta-analysis suggests that LVI may be a poor prognostic factor for stage I/II CRC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.